Skip to content

A Multicenter Randomized Open-Label Parallel-Controlled Clinical Study on Combined Anti-Reflux Mucosal Resection (ARMS) and Peroral Endoscopic Cardial Constriction (PECC) for Refractory Gastroesophageal Reflux Disease (GERD)

A Multicenter Randomized Open-Label Parallel-Controlled Clinical Study on Combined Anti-Reflux Mucosal Resection (ARMS) and Peroral Endoscopic Cardial Constriction (PECC) for Refractory Gastroesophageal Reflux Disease (GERD)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600129278
Enrollment
Unknown
Registered
2026-08-03
Start date
2026-09-01
Completion date
Unknown
Last updated
2026-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroesophageal reflux disease

Interventions

Experimental group (ARMS + PECC):ARMS combined with PECC surgery
Control group (?Esomeprazole medication group) :Esomeprazole 20 mg orally once daily

Sponsors

Taikang Xianlin Drum Tower Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Aged 18 years or older and under 80 years old. 2.Under full-course PPI/P-CAB therapy, symptoms of heartburn, regurgitation and/or chest pain have persisted for at least 3 months with episodes occurring no less than 3 times per week. 3.24-hour ambulatory pH-impedance monitoring: Esophageal acid exposure time =4% 4.FSSG score = 10 points Refractory GERD or PPI-dependent GERD

Exclusion criteria

Exclusion criteria: 1.American Society of Anesthesiologists (ASA) physical status classification is Class III or higher. 2.Previous history of anti-reflux surgery (surgical or endoscopic). 3.Previous history of gastric or esophageal surgery. 4.Hiatal hernia greater than 2 cm. 5.Grade C or D esophagitis. 6.Presence of Barrett's esophagus with dysplasia. 7.Known coagulation disorders. 8.Unable to discontinue anticoagulant drugs. 9.Presence of liver cirrhosis and/or esophageal varices. 10.Presence of esophageal stricture. 11.Presence of eosinophilic esophagitis. 12.Severe esophageal motility disorders such as achalasia and aperistalsis. 13.Presence of connective tissue diseases. 14.Pregnancy at the time of treatment.

Design outcomes

Primary

MeasureTime frame
Functional Symptom Score for GERD (FSSG) at 6 months post-surgery;

Secondary

MeasureTime frame
Gastroesophageal Reflux Disease Questionnaire (Gerd-Q) score at 6 months post-surgery;Gastroesophageal Reflux Disease Quality of Life Score (GERD-HRQL)at 6 months post-surgery;Patient subjective satisfaction score;Proportion and dosage of postoperative omeprazole use ;

Countries

China

Contacts

Public ContactZou Xiaoping

Taikang Xianlin Drum Tower Hospital

zouxp03@tkhealthcare.com+86 130 0256 9680

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Aug 25, 2026